Mohaupt M G, Vogt B, Frey F J
Division of Nephrology and Hypertension, Inselspital, University of Berne, CH-3010 Bern, Switzerland.
Transplantation. 2001 Jul 15;72(1):162-4. doi: 10.1097/00007890-200107150-00031.
The immunosuppressant sirolimus is effective in preventing acute rejection episodes. So far, unusual edema formation has not been reported as a side effect.
Two groups of patients with renal transplants, consisting of 11 patients each, were followed for up to 29 months. The immunosuppressive regimen was either sirolimus and prednisone with or without cyclosporine or azathioprine/mycophenolate and prednisone with cyclosporine. Routine follow-up included a thorough clinical investigation. Edema formation was documented photographically.
In 5 of the 11 patients treated with sirolimus uni- or bilateral, non-itching, eyelid edema was observed. After discontinuation of sirolimus, lid edema disappeared. The duration until recovery varied from weeks to months. No cause of edema formation other than the treatment with sirolimus was detected.
Severe eyelid edema formation seems to be associated with sirolimus treatment. The underlying mechanism is unknown.
免疫抑制剂西罗莫司在预防急性排斥反应方面有效。迄今为止，尚未有异常水肿形成作为副作用的报道。
两组肾移植患者，每组11例，随访长达29个月。免疫抑制方案为西罗莫司与泼尼松联用或不联用环孢素或硫唑嘌呤/霉酚酸酯，以及泼尼松与环孢素联用。常规随访包括全面的临床检查。水肿形成情况通过拍照记录。
在接受西罗莫司治疗的11例患者中，有5例出现单侧或双侧、无瘙痒的眼睑水肿。停用西罗莫司后，眼睑水肿消失。恢复所需时间从数周至数月不等。除西罗莫司治疗外，未检测到其他水肿形成原因。
严重眼睑水肿形成似乎与西罗莫司治疗有关。其潜在机制尚不清楚。
